Transforming growth factor-β and angiotensin in fibrosis and burn injuries

Journal of Burn Care and Research

Volumn 30, Issue 3, 2009, Pages 471-481

  Gabriel, Vincent Ashley ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GAMMA INTERFERON; LOSARTAN; LOSARTAN POTASSIUM; PACLITAXEL; PROPRANOLOL; RAMIPRIL; RENIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TRICHOSTATIN A; ANGIOTENSIN DERIVATIVE; SMAD PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; BURN; BURN PATIENT; BURN SCAR; CATECHOLAMINE RELEASE; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HYPERMETABOLISM; HYPERTENSION; HYPERTROPHIC SCAR; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; KELOID; KIDNEY FIBROSIS; LUNG FIBROSIS; LUNG INJURY; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCLERODERMA; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TISSUE TYPES; TREATMENT OUTCOME; LOCALIZED SCLERODERMA; METABOLISM;

ANGIOTENSINS; BURNS; FIBROSIS; HUMANS; MYOCARDIAL INFARCTION; SCLERODERMA, LOCALIZED; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 67849095348     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3181a28ddb     Document Type: Review

References (109)

1. Esselman PC. Burn rehabilitation: an overview. Arch Phys Med Rehabil 2007;88:S3-S6.
2. Engrav LH, Garner WL, Tredget EE. Hypertrophic scar, wound contraction and hyper-hypopigmentation. J Burn Care Res 2007;28:593-597
3. Pennison M, Pasche B. Targeting transforming growth factor-B signaling. Curr Opin Oncol 2007;19:579-585
4. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carva-jal G, Egido J. TGF-B signalling in vascular fibrosis. Cardio-vasc Res 2007;74:196-206.
5. McLean CA, Cleland H, Moncrieff NJ, Barton RJ, de Kretser DM, Phillips DJ. Temporal expression of activin in acute burn wounds-from inflammatory cells to fibroblasts. Burns 2008; 34:50-55.
6. Wang J, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Increased TGF-beta-producing CD4- T lymphocytes in postburn patients and their potential interaction with dermal fibroblasts in hypertrophic scarring. Wound Repair Regen 2007;15:530-539.
7. Annes JP, Munger JS, Rikfin DB. Making sense of latent TGF-beta activation. J Cell Sci 2003;116:217-224.
8. Leask A, Abraham DJ. TGF-B signaling and the fibrotic response. FASEB J 2004;18:816-827.
9. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-B signaling in regulation of cell growth and differentiation. Immunol Lett 2002;82:85-91.
10. Javelaud D, Mauviel A. Mammalian transforming growth factor betas: Smad signalling and physio-pathological roles. Int J Biochem Cell Biol 2004;36:1161-1165.
11. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783-2810.
12. Hill CS. The Smads. Int J Biochem Cell Biol 1999;31: 1249-1254.
13. Ikedo H, Tamaki K, Ueda S, et al. Smad protein and TGF-B signaling in vascular smooth muscle cells. Int J Mol Med 2003;11:645-650.
14. Weir M. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29: 1803-1824.
15. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003;73-79.
16. Tuñón J, Ruiz-Ortega M, Egido J. Regulation of matrix pro- teins and impact on vascular structure. Curr Hypertens Rep 2000;2:106-113.
17. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005;111:2509-2517.
18. Ma LJ, Yang HC, Gaspert A, et al. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in b6(-/-) mice. Am J Pathol 2003;163:1261-1273.
19. Wang WS, Huang XR, Canlas E, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006;98: 1032-1039.
20. Kopp J, Preis E, Said H, et al. Abrogation of transforming growth factor-beta signaling by SMAD7 inhibits collagen gel contraction of human dermal fibroblasts. J Biol Chem 2005; 280:21570-21576.
21. Phan TL, Lim IJ, Aalami O, et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J Pathol 2005;207:232-242.
22. Yurovsky VV, Gerzanich V, Ivanova S, Dong Y, Tsymbalyuk O, Simard JM. Autocrine TGF-beta(1) mediates angiotensin II-Induced proliferative response of cerebral vessels in vivo. Am J Hypertens 2007;20:950-956.
23. Rodriguez-Vita J, Diaz J, Sanchez-Lopez E, et al. Angioten-sin II activates the Smad signaling pathway: potential role in vascular fibrosis. Circulation 2004;110:87-187.
24. Pokharel S, van Geel PP, Sharma UC, et al. Increased myo-cardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phos-phorylation of Smad2/3. Circulation 2004;110:3129-3135.
25. Ikeda Y, Aihara K, Sato T, et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 2005;280:29661-29666/
26. Ko SH, Hong OK, Kim JW, et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem 2006;98:343-355.
27. Kose O, Waseem A. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg 2008; 34:336-346.
28. Chin GS, Liu W, Peled Z, et al. Differential expression of transforming growth factor-[beta] receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001;108:423-429.
29. Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen 2004;12:546-556.
30. Fumagalli M, Musso T, Vermi W, et al. Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin. Exp Dermatol 2007;16:600-610
31. Gao Z, Wang Z, Shi Y, et al. Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. Plast Reconstr Surg 2006;118:1328-1337
32. Wang Z, Gao Z, Shi Y, et al. Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg 2007;60:1193-1199
33. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in kerati-nocyte-fibroblast coculture contributes to keloid pathogene-sis. J Cell Physiol 2006;208:336-343
34. Colwell AS, Yun R, Krummel TM, Longaker MT, Lorenz HP. Keratinocytes modulate fetal and postnatal fibroblast transforming growth factor-beta and Smad expression in co-culture. Plast Reconstr Surg 2007;119:1440-1445.
35. Colwell AS, Krummel TM, Longaker MT, Lorenz HP. Fetal and adult fibroblasts have similar TGF-beta-mediated, Smad- dependent signaling pathways. Plast Reconstr Surg 2006; 117:2277-2283.
36. Rolfe KJ, Richardson J, Vigor C, Irvine LM, Grobbelaar AO, Linge C. A role for TGF-beta1-induced cellular responses during wound healing of the non-scarring early human fetus? J Invest Dermatol 2007;127:2656-2667.
37. Steckelings UM, Wollschlager T, Peters J, Henz BM, Hermes B, Artuc M. Human skin: source of and target organ for angiotensin II. Exp Dermatol 2004;13:148-154.
38. Liu HW, Cheng B, Yu WL, et al. Angiotensin II regulates phosphoinositide 3 kinase/Akt cascade via a negative crosstalk between AT(1) and AT(2) receptors in skin fibro-blasts of human hypertrophic scars. Life Sci 2006;79: 475-483.
39. Steckelings UM, Henz BM, Wiehstutz S, Unger T, Artuc M. Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol 2005;153:887-893.
40. Nickenig G, Geisen G, Vetter H, Sachinidis A. Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 1997;75:217-222.
41. Takeda H, Katagata Y, Hozumi Y, Kondo S. Effects of an-giotensin II skin wound healing receptor signaling during. Am J Pathol 2004;165:1653-1662.
42. Iannello S, Milazzo P, Bordonaro F, Belfiore F. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid-two case reports and literature review. Med-GenMed 2006;8:60.
43. Morihara K, Takai S, Takenaka H, et al. Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J Am Acad Dermatol 2006;54: 251-257.
44. Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165: 203-217.
45. Santiago B, Gutierrez-Cañas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450-455.
46. Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon-A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56:3837-3846.
47. Qi W, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006;69:989-995.
48. Goto Y, Manabe N, Uchio-Yamada K, et al. Augmented cy-toplasmic Smad4 induces acceleration of TGF-beta1 signaling in renal tubulointerstitial cells of hereditary nephrotic ICGN mice with chronic renal fibrosis; possible role for myo-fibroblastic differentiation. Cell Tissue Res 2004;315: 209-221.
49. Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005;16:2702-2713.
50. Phanish MK, Wahab NA, Hendry BM, Dockrell ME. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol 2005;100:e156-e165.
51. Ka SM, Huang XR, Lan HY, et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007;18:1777-1788.
52. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephrop-athy in mice. Proc Natl Acad Sci USA 2004;101:8687-8692.
53. Dixon A, Maric C. 17beta-Estradiol attenuates diabetic kid- ney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol 2007;293:F1678-F1690.
54. Heeg MH, Kozialek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005; 68:96-109.
55. Kelly DJ, Zhang Y, Cox AJ, Gilbert RE. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006;69:1954-1960.
56. Pfeffer MA, Braunwald E. Ventricular remodeling after myo-cardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
57. Hao J, Ju H, Zhao S, Junaid A, Scammell-La Fleur T, Dixon IM. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999;31:667-678.
58. Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007;116:2127-2138.
59. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 2002;282:H1685-H1696.
60. Luzina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006;206:221-228.
61. Pham TN, Cho KH, Adamson LK, et al. Burn injury induces an inhibitory signal in the lung Smad pathway. Cytokine 2004;27:66-73.
62. Saika S, Yamanaka O, Okada Y, et al. Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. Am J Physiol Cell Physiol 2007;293:C75-C86.
63. Saika S, Ikeda K, Yamanaka O, et al. Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing. Am J Pathol 2006;168:1848-1860.
64. Yamanaka O, Saika S, Ikeda K, Miyazaki KI, Ohnishi Y, Ooshima A. Interleukin-7 modulates extracellular matrix production and TGF-beta signaling in cultured human sub-conjunctival fibroblasts. Curr Eye Res 2006;31:491-499.
65. Yamanaka O, Ikeda K, Saika S, Miyazaki K, Ooshima A, Ohnishi Y. Gene transfer of Smad7 modulates injury-induced conjunctival wound healing in mice. Mol Vis 2006;12: 841-851.
66. Saika S, Yamanaka O, Nishikawa-Ishida I, et al. Effect of Smad7 gene overexpression on transforming growth factor beta-induced retinal pigment fibrosis in a proliferative vitreo-retinopathy mouse model. Arch Ophthalmol 2007;125: 647-654.
67. Shirai K, Saika S, Tanaka T, et al. A new model of anterior subcapsular cataract: involvement of TGF beta/Smad signaling. Mol Vis 2006;12:681-691.
68. Zanninelli G, Vetuschi A, Sferra R, et al. Smad3 knock-out mice as a useful model to study intestinal fibrogenesis. World J Gastroenterol 2006;12:1211-1218.
69. Wang Y, Moges H, Bharucha Y, Symes A. Smad3 null mice display more rapid wound closure and reduced scar formation after a stab wound to the cerebral cortex. Exp Neurol 2007; 203:168-184.
70. Blaney Davidson EN, Vitters EL, van den Berg WB, van der Kraan PM. TGF beta-induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad7. Arthritis Res Ther 2006;8:R65.
71. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65:744-752.
72. Mori Y, Ishida W, Bhattacharyya S, Li YZ, Platanias LC, Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004;50: 4008-4021.
73. Belmadani S, Bernal J, Wei CC, et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated an-giotensin II. Am J Pathol 2007;171:777-789.
74. Wang JF, Jiao HY, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Improvement in postburn hypertrophic scar after treatment with IFN-alpha 2b is associated with decreased fibrocytes. J Interferon Cytokine Res 2007;27:921-930.
75. Dooley S, Said HM, Gressner AM, et al. Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. J Biol Chem 2006;281:1784-1795.
76. Huang ZY, Pereira C, Toliver-Kinsky T, et al. Effect of transforming growth factor-beta neutralization on survival and bacterial clearance in a murine model of Pseudomonas aeruginosa burn wound infection. J Burn Care Res 2006; 27:682-687.
77. Sakallioglu AE, Basaran O, Ozdemir BH, Arat Z, Yucel M, Haberal M. Local and systemic interactions related to serum transforming growth factor-beta levels in burn wounds of various depths. Burns 2006;32:980-985.
78. Ishikawa K, Nishimura T, deSerres S, Meyer AA. The effects of transforming growth factor-beta neutralization on post-burn humoral immunity. J Trauma 2004;57:529-536.
79. Nishimura T, Nishiura T, deSerres S, Nakagawa T, Meyer AA. Transforming growth factor-beta 1 and splenocyte apo-ptotic cell death after burn injuries. J Burn Care Rehabil 2000;21:128-134.
80. Hobson KG, Cho K, Adamson LK, Greenhalgh DG. Burn-induced thymic apoptosis corresponds with altered TGF-beta(1) and Smad 2/3. J Surg Res 2002;105:4-9.
81. Yeh FL, Shen HD, Fang RH. Deficient transforming growth factor beta and interleukin-10 responses contribute to the septic death of burned patients. Burns 2002;28:631-637.
82. Wang JF, Jiao HY, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 2007;15: 113-121.
83. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type I receptors during sepsis. Hypertension 2001;38:177-182.
84. Hilton JG, Marullo DS. Trauma induced increases in plasma vasopressin and angiotensin-II. Life Sci 1987;41: 2195-2200.
85. Tadros T, Traber DL, Herndon DN. Trauma- and sepsis-induced hepatic ischemia and reperfusion injury-role of an-giotensin II. Arch Surg 2000;135:766-772.
86. Tadros T, Traber DL, Heggers JP, Herndon DN. Angio-tensin II inhibitor DuP753 attenuates burn- and endotox-in-induced gut ischemia, lipid peroxidation, mucosal permeability, and bacterial translocation. Ann Surg 2000;231: 566-576.
87. Gennari R, Alexander JW, Boyce ST, Lilly N, Babcock GF, Cornaggia M. Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge. Shock 1996;6:95-100.
88. Kasper SO, Castle SM, Daley BJ, Enderson BL, Karlstad MD. Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury. Shock 2006;26:485-488.
89. Tredget EE, Shankowsky HA, Taerum TV, Moysa GL, Alton JD. The role of inhalation injury in burn trauma. A Canadian experience. Ann Surg 1990;212:720-727.
90. Smith DL, Cairns BA, Ramadan F, et al. Effect of inhalation injury, burn size, and age on mortality: a study of 1447 consecutive burn patients. J Trauma 1994;37:655-659.
91. Clark WR, Molteni A, Nieman G, Briziomolteni L, Solliday NH. Effect of acute smoke inhalation on angiotensin con- verting enzyme, plasminogen- activator, and angiotensin-II in the dog. Ann Clin Lab Sci 1989;19:452-460.
92. Briziomolteni L, Piano G, Warpeha RL, et al. Angiotensin-1-converting enzyme-activity as index of pulmonary damage in thermal-injury with or without smoke-inhalation. Ann Clin Lab Sci 1992;22:1-10.
93. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166: 646-650.
94. Wilmore DW, Long JM, Mason AD, Skreen RW, Pruitt BA. Catecholamines- mediator of hypermetabolic response to thermal injury. Ann Surg 1974;180:653-669.
95. Herndon DN, Nguyen TT, Wolfe RR, et al. Lipolysis in burned patients is stimulated by the beta(2)-receptor for cat-echolamines. Arch Surg 1994;129:1301-1305.
96. Cassuto J, Tarnow P, Yregard L, Lindblom L, Rantfors J. Regulation of postburn ischemia by alpha- and beta-adrenoceptor subtypes. Burns 2005;31:131-137.
97. Cassuto J, Tarnow P, Yregard L, Lindblom L, Rantfors J. Adrenoceptor subtypes in the control of burn-induced plasma extravasation. Burns 2005;31:123-129.
98. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001;345:1223-1229.
99. Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Hern-don DN. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 2007;62:676-681.
100. Arbabi S, Ahrns KS, Wahl WL, et al. Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma 2004;56:265-269.
101. Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR. Effect of propranolol administration on hemody- namic and metabolic responses of burned pediatric-patients. Ann Surg 1988;208:484-492.
102. Foucart S, Dechamplain J, Nadeau R. Modulation by Beta-adrenoceptors and angiotensin-II receptors of splanchnic nerve evoked catecholamine release from the adrenal-medulla. Can J Physiol Pharmacol 1991;69:1-7.
103. Critchley L, Ding BG, Fok B, et al. The effects of candesartan and ramipril on adrenal catecholamine release in anaesthe-tized dogs. Eur J Pharmacol 2004;489:67-75.
104. Wang JM, Slembrouck D, Tan JH, et al. Presence of cellular renin-angiotensin system in chromaffin cells of bovine adrenal medulla. Am J Physiol Heart Circ Physiol 2002;283: H1811-H1818.
105. Cavadas C, Grand D, Mosimann F, et al. Angiotensin II mediates catecholamine and neuropeptide - secretion in human adrenal chromaffin cells through the AT(1) receptor. Regul Pept 2003;111:61-65.
106. Gonzalezgarcia C, Keiser HR. Angiotensin-II and angioten-sin converting enzyme binding in human adrenal-gland and pheochromocytomas. J Hypertens 1990;8:433-441.
107. Ghosh AK, Wei J, Wu M, Varga J. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-[gamma]. Biochem Biophys Res Comm 2008;19:231-236.
108. Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lind-holm B. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflamma-tory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin Nephrol 2007;68: 295-301.
109. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother 2006;40: 1998-2002.